ASX Announcement

31 May 2022

emyria
myriad data.
individual care.

Emyria expands MDMA analogue program with the University of Western Australia

*"Emyria's clinical development expertise, funding and international networks have taken our **MDMA analogue research to the next level**.*

*We have already identified hits for **new disease indications** as a result of the screening program this collaboration has enabled. We are excited at the prospect of **translating these findings** to the clinic, where they can **improve quality of life for patients with unmet needs.**"*

UWA Professor - Matt Piggott

Highlights:

- Emyria, and partner the University of Western Australia (UWA), have agreed to substantially expand their collaboration to develop novel MDMA-like medicines ("MDMA analogues") with potential to become treatments for major unmet needs
- To date, 85 compounds have been successfully screened with several compounds being prepared for preclinical testing to determine their therapeutic potential
- MDMA analogue program is a key pillar of Emyria's drug development pipeline (*see p3*) by providing exclusive access to promising new compounds with potential as:
  - Novel MDMA analogues to assist with psychotherapy (i.e. *"next-generation psychedelic-assisted therapeutics"*) for major mental health disorders and;
  - New treatments for a range of neurological and non-neurological conditions
- Additional investment expected to accelerate additional compound synthesis and screening through team expansion, specialist materials, equipment and software as well as commercialisation of library via multiple patent family filing
- Emyria CEO, Michael Winlo to provide webinar on Emyria's drug pipeline 01 June 2022. Register here: **https://janemorganmanagement-au.zoom.us/j/81626179616**

Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech developing treatments for unmet needs powered by real-world patient data, is pleased to announce a substantial expansion of an exclusive partnership with the University of Western Australia to build and screen a proprietary MDMA analogue library.

The initial novel library of over 100 unique compounds has been developed by a highly regarded research group led by expert medicinal chemist, Dr. Matt Piggott, who has been working with MDMA analogues, and exploring their therapeutic potential, for over 10 years.

Positive initial results reveal 82 of the first 85 compounds screened by Eurofins show no signs of off-target effects. *(See ASX releases 08 Dec 2021 and 20 May 2021)* allowing these compounds to advance to preclinical models while additional compounds are being synthesised and prepared for screening with support from a global team of advisors. *(See ASX announcements 20 Aug 2021 and 16 Sep 2021)*

Emyria's Managing Director, Dr. Michael Winlo said: *"Emyria's partnership with UWA has been very productive. We're proud to continue our support of the development, commercialisation and translation of this promising and unique compound library developed by Professor Matt Piggott and his team.*

Initial screening results have been very positive. In a short timeframe, we have identified several promising lead drug candidates which we are now advancing to preclinical screening.

This additional funding will help us further expand the library and build a strong patent and translational strategy with our global team.

This MDMA partnership is a core part of Emyria's growing drug development pipeline and complements our ultra-pure cannabinoid program led by EMD-RX5.

I look forward to updating the market as we advance against our development milestones in the coming months."

Under the expanded agreement, Emyria will provide an additional $450,000 to UWA and Dr. Matt Piggott's research group over the next 12 months. This funding follows on from the initial agreement entered into with UWA in August 2021. Upon completion, as per the prior agreement, Emyria holds an exclusive option to license and commercialise the most promising compounds (and their associated patent families).
(see ASX release 05 Aug 2021).

Professor Matt Piggott said: *"Emyria's clinical development expertise, funding and international networks have taken our MDMA analogue research to the next level.*

We have already identified hits for new disease indications as a result of the screening program this collaboration has enabled. We are excited at the prospect of translating these findings to the clinic, where they can improve quality of life for patients with unmet needs."



Prof. Matt Piggott

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information:

Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com

Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com

Investor webinar details

Wednesday 1st June at 11:00 am AEST.

Emyria's Managing Director and CEO, Dr, Michael Winlo will present an update on the MDMA analogue program with UWA and the recently announced positive Phase 1 trial data for the **EMD-RX5** crossover study with Epidyolex®, the only TGA and FDA registered CBD medicine, indicating excellent bioavailability, safety and tolerability among 12 healthy and demographically diverse volunteer subjects.

Details of the event are as follows:

- **Event:** Emyria Drug Development Webinar
- **Webinar Presenter:** Emyria's Managing Director and CEO, Dr. Michael Winlo
- **Date and Time:** Wednesday 1st June, 11:00am Sydney time (AEST)
- **Where**: Zoom Webinar - details to be provided upon registration

To register, please click on the link below:
https://janemorganmanagement-au.zoom.us/j/81626179616

After registering your interest, you will receive a confirmation email with information about joining the webinar. Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to Lexi O'Halloran at: lexi@janemorganmanagement.com.au

emyria

DRUG DEVELOPMENT **PIPELINE**

PLANNING PHASE · ACTIVE MODE · FAST TRACKED WITH REAL WORLD DATA · COMPLETE

ULTRA-PURE **CANNABINOID MEDICINES**

EMYRIA'S ULTRA-PURE CANNABINOID TREATMENTS have been uniquely formulated to:

- Meet FDA requirements for registered medicines
- Have improved bioavailability
- Meet patient preferences for a solid, oral dose form

Proprietary **REAL WORLD DATA** supports **EMYRIA'S ACCELERATED REGISTRATION PROGRAMS,** carefully gathered with over **6,000 patients** *(and growing)* receiving personalised cannabinoid treatment across Emyria's clinical service subsidiary.

CLINICAL PROGRAMS

	PRE-CLINICAL DOSE DEV.	CLINICAL DEV. PROGRAM PHASES P1	P2	P3	REGISTRATION PROGRESS AUSTRALIA TGA	USA FDA
EMD-RX5 Over-the-counter treatment for symptoms of psychological distress	✓	✓	✓ FT RWD	PLANNING		
EMD-RX5 Over-the-counter treatment for symptoms of IBS	✓	✓	✓ FT RWD	PLANNING		
EMD-RX7 ULTRA-PURE, prescription CBD treatment for Multiple Medical Conditions *	✓	PLANNING				
Other **ULTRA PURE** HIGH BIOAVAILABILITY CBD FORMULATIONS ***in development*** targeting unmet needs	PLANNING					

* *To be determined*

NEXT-GEN **MDMA LIKE MEDICINE**

Emyria is developing a **one-of-a-kind**, proprietary library of **OVER 100 UNIQUE COMPOUNDS** *(& growing)* Inspired by -3. 4 -Methylenedioxymethamphetamine *(also known as "MDMA" or "ecstasy")* and developed over ten years by Dr. Matt Piggott and his team at the University of Western Australia.

ADVANCED CLINICAL & IP DEVELOPMENT STRATEGY focussed on identifying novel small molecules with potential to become registered treatments as:

- Next-generation psychedelic-assisted therapies
- Novel neurological therapies
- Novel non-neurological therapies

THERAPEUTIC FOCUS AREA

	PRE-CLINICAL DEV. NEW COMPOUND	ADVANCE SCREENING	CLINICAL DEV. PROGRAM PHASES PRE-CLIN. TRIALS	LEAD SELECTION	CLIN. TRIALS	REGISTRATION PROGRESS AUSTRALIA TGA	USA FDA
NEXT-GEN MDMA Targeting PTSD psychedelic-assisted therapies for neurological *(Parkinson's)* and non - neurological disorders	A	A	PLANNING				

About Emyria (emyria.com)

Emyria Limited develops biopharmaceuticals guided by proprietary Real-World Data collected with patients across its wholly-owned clinical service subsidiary, Emerald Clinics.

Emyria's current clinical development programs are focussed on the registration of proprietary formulations of cannabinoid-based medical treatments (CBMTs) and novel MDMA ('ecstasy') analogues with major global regulators. Emyria's programs target major unmet needs such as mental health disorders and chronic pain.

Emyria's Real World Data (RWD) guides each of Emyria's clinical development programs and care models. Emyria RWD is deep, ethically-sourced clinical evidence gathered with thousands of patients who also receive personalised care at Emerald Clinics.

Emyria is therefore uniquely providing care to patients, generating clinical evidence and advancing multiple proprietary treatment programs towards registration.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.